Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2036772 | Cell | 2010 | 12 Pages |
SummaryFibrillar protein aggregates are the major pathological hallmark of several incurable, age-related, neurodegenerative disorders. These aggregates typically contain aggregation-prone pathogenic proteins, such as amyloid-beta in Alzheimer's disease and alpha-synuclein in Parkinson's disease. It is, however, poorly understood how these aggregates are formed during cellular aging. Here we identify an evolutionarily highly conserved modifier of aggregation, MOAG-4, as a positive regulator of aggregate formation in C. elegans models for polyglutamine diseases. Inactivation of MOAG-4 suppresses the formation of compact polyglutamine aggregation intermediates that are required for aggregate formation. The role of MOAG-4 in driving aggregation extends to amyloid-beta and alpha-synuclein and is evolutionarily conserved in its human orthologs SERF1A and SERF2. MOAG-4/SERF appears to act independently from HSF-1-induced molecular chaperones, proteasomal degradation, and autophagy. Our results suggest that MOAG-4/SERF regulates age-related proteotoxicity through a previously unexplored pathway, which will open up new avenues for research on age-related, neurodegenerative diseases.
Graphical AbstractFigure optionsDownload full-size imageDownload high-quality image (159 K)Download as PowerPoint slideHighlights► MOAG-4 promotes aggregation of aggregation-prone disease proteins ► Inactivation of MOAG-4 suppresses age-related proteotoxicity ► MOAG-4 regulates proteotoxicity independently of HSF-1 and DAF-16 ► The role of MOAG-4 is evolutionarily conserved in human SERF1A and SERF2